Onyema Ogbuagu, CROI 2022: Long-acting Lenacapavir in People with Multidrug Resistant HIV – Week 52 Results
Lenacapavir, a potent first-in-class inhibitor of HIV-1 capsid function, is in development for treatment and prevention of HIV-1 infection. Dr Onyema Ogbuagu (Yale School of Medicine, New Haven, CT, USA) discusses the ongoing phase 2/3 CAPELLA study, investigating lenacapavir in combination with an optimized background regimen treatment-experienced people with HIV-1, with multidrug-resistance and ongoing viremia.
The abstract entitled: ‘Long-Acting Lenacapavir in People with Multidrug Resistant HIV-1: Week 52 Results’ (Abstract #496) was presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2022 (Virtual), 12-16 February 2022.
- What are the unmet needs of people living with HIV infection? (0:14)
- What is the mechanism of action of lenacapavir and what are its potential advantages over existing HIV therapies? (1:21)
- What were the aims, methodology and findings of the CAPELLA trial? (3:02)
- What will be the next steps in the clinical development of lenacapavir in this indication? (7:57)
Disclosures: Onyema Ogbuagu is on advisory boards for Gilead Sciences and ViiV Healthcare and a speaker’s Bureau participant for Gilead Sciences.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of CROI 2022.
Share this Video
Related Videos In HIV
Sunil Solomon, CROI 2023: Unknowns and hurdles surrounding long-acting injectable PrEP for the prevention of HIV
touchINFECTIOUSDISEASES were delighted to speak with Dr Sunil Solomon (The Johns Hopkins University School of Medicine, Baltimore, MD, USA) about the hurdles surrounding the use of long-acting injectable pre-exposure prophylaxis (PrEP) for the prevention of HIV in at-risk populations. Dr Solomon discussed the main barriers to conducting HIV research in at-risk populations, such as people […]
Sunil Solomon, CROI 2023: Current knowledge surrounding long-acting injectable PrEP for the prevention of HIV
It was a pleasure to talk with Dr Sunil Solomon (The Johns Hopkins University School of Medicine, Baltimore, MD, USA) about the evidence from clinical trials for the use of long-acting injectables in the prevention of HIV and how long-acting injectable cabotegravir compares to oral pre-exposure prophylaxis (PrEP). Dr Solomon also discussed who is most […]
Nyaradzo Mgodi, CROI 2023: Long-acting injectable PrEP and cabotegravir roll-out for prevention of HIV- Factors affecting clinical practice and policy making
Long-acting injectable pre-exposure prophylaxis (PrEP) with cabotegravir has recently been approved as a new HIV prevention method. The preventative treatment involves receiving an injection of cabotegravir every two months to prevent HIV infection, rather than taking daily oral medication. The roll-out of this new prevention method is affected by several factors in both clinical practice […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!